Company / Return on Assets (ROA)
Actinium Pharmaceuticals, Inc. Return on Assets (ROA) History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-65.5%
FY2025
5-year range
-65.5% / -21.7%
FY2021-FY2025
Trend
-3.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Assets (ROA) has declined for 3 consecutive years, from -21.7% in FY2022 to -65.5% in FY2025.
Based on SEC 10-K filings.
-65.5% in FY2025 with a 3-year CAGR of -43.8%.
Declined from -40.5% to -65.5% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -43.8pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- Actinium Pharmaceuticals, Inc.'s return on assets (roa) has declined for 3 consecutive years.
- In FY2025, return on assets (roa) decreased 3.1% year-over-year.
- Peak return on assets (roa) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -65.5% | -3.1% |
| FY2024 | -63.5% | -56.6% |
| FY2023 | -40.5% | -86.8% |
| FY2022 | -21.7% | +21.5% |
| FY2021 | -27.6% | +50.3% |
| FY2011 | -55.6% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026